Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹420.45.
28 Oct: open ₹420.95, high ₹430.70, low ₹414.15
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,249 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,56,95560.7% delivered
Gufic Biosciences share news and announcements
608 announcements, routine notices left out, newest first. Page 5 of 13.
Jun 2022
3 Jun · Related Party Transaction
May 2022
24 May · Analysts
20 May · Results
17 May · Analysts
Apr 2022
19 Apr · Board meeting
7 Apr · Rating
7 Apr · Rating
Mar 2022
23 Mar · Analysts
21 Mar · Board meeting
16 Mar · Communication to shareholders as per Reg 30
Feb 2022
9 Feb · Board meeting
9 Feb · Results
7 Feb · Analysts
2 Feb · Board meeting
Jan 2022
Dec 2021
20 Dec · Meeting
10 Dec · Updates
Nov 2021
8 Nov · Analysts
3 Nov · Results
Oct 2021
27 Oct · Board meeting
27 Oct · Rating
4 Oct · Board meeting
Sep 2021
21 Sep · Meeting
Aug 2021
19 Aug · Analysts
17 Aug · Analysts
13 Aug · Analysts
11 Aug · Board meeting
11 Aug · Results
11 Aug · Analysts
9 Aug · Analysts
Jul 2021
2 Jul · Related Party Transactions
Jun 2021
14 Jun · Analysts